Loading...

LUNG - Pulmonx Corporation

Analyst Downgrade Signal for 02-23-2024
Analyst Downgrade Signal: LUNG from Overweight to Equal Weight by Wells Fargo
Price Target: $16>>14


Loading Chart LUNG

Stock Signal Information


Signal

Analyst Downgrade Signal: LUNG from Overweight to Equal Weight by Wells Fargo
Price Target: $16>>14
Report Date: 02-23-2024
Symbol: LUNG - Pulmonx Corporation
Sector: Healthcare
Industry: Medical Devices
Analyst Downgrade Signal: LUNG from Overweight to Equal Weight by Wells Fargo
Price Target: $16>>14

  LUNG Technical Analysis

Company Contact

Pulmonx Corporation (LUNG)
700 Chesapeake Drive
Redwood City, CA 94063
Phone: 650-364-0400
Website: https://pulmonx.com
CEO: Mr. Glendon E. French

LUNG, Pulmonx Corporation

LUNG Pulmonx Corporation Logo Image

NASDAQ, Nasdaq Global Select


Company Profile

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in Europe, the Middle East, Africa, the Asia-Pacific, the United States, and internationally. Pulmonx Corporation was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.